- Home
- MANU vs IOVA Comparison
MANU vs IOVA Comparison
Compare MANU & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MANU
- IOVA
- Stock Information
- Founded
- MANU 1878
- IOVA 2007
- Country
- MANU United Kingdom
- IOVA United States
- Employees
- MANU N/A
- IOVA N/A
- Industry
- MANU Services-Misc. Amusement & Recreation
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MANU Consumer Discretionary
- IOVA Health Care
- Exchange
- MANU Nasdaq
- IOVA Nasdaq
- Market Cap
- MANU 2.9B
- IOVA 3.0B
- IPO Year
- MANU 2012
- IOVA N/A
- Fundamental
- Price
- MANU $16.96
- IOVA $8.18
- Analyst Decision
- MANU Hold
- IOVA Strong Buy
- Analyst Count
- MANU 1
- IOVA 9
- Target Price
- MANU $18.50
- IOVA $23.33
- AVG Volume (30 Days)
- MANU 258.2K
- IOVA 7.8M
- Earning Date
- MANU 09-11-2024
- IOVA 11-07-2024
- Dividend Yield
- MANU N/A
- IOVA N/A
- EPS Growth
- MANU N/A
- IOVA N/A
- EPS
- MANU N/A
- IOVA N/A
- Revenue
- MANU $836,320,093.00
- IOVA $90,858,000.00
- Revenue This Year
- MANU $2.71
- IOVA $13,827.67
- Revenue Next Year
- MANU $8.90
- IOVA $183.70
- P/E Ratio
- MANU N/A
- IOVA N/A
- Revenue Growth
- MANU 2.06
- IOVA 12751.20
- 52 Week Low
- MANU $13.50
- IOVA $4.44
- 52 Week High
- MANU $22.00
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- MANU 51.32
- IOVA 32.59
- Support Level
- MANU $15.81
- IOVA $9.31
- Resistance Level
- MANU $18.12
- IOVA $10.86
- Average True Range (ATR)
- MANU 0.40
- IOVA 0.71
- MACD
- MANU 0.05
- IOVA -0.37
- Stochastic Oscillator
- MANU 49.57
- IOVA 1.48
About MANU Manchester United Ltd.
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, and sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which the majority of the revenue is generated including Commercial, Broadcasting, and Matchday.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.